PRICE SENSITIVE INFORMATION

This is to information of all concerned that the 254th Board Meeting of JMI Syringes & Medical Devices Limited was held on Thursday, November 12, 2026 at 2.30 P.M. Dhaka time through Digital Platform and approved the Q1 Un-Audited Financial Statements for the period ended September 30, 2026 and disclosed the following financial indicators of the Company in compliance with the guidelines of the respective regulatory authorities:

Amount in BDT

Particulars		Q1-From July 2026 to September 2026	Q1-From July 2025 to September 2025
i) Net Profit after Tax	:	1,25,08,147.37	(1,49,01,193.38)
ii) Earnings Per Share (EPS)	:	0.42	(0.50)
iii) Net Operating Cash Flow Per Share (NOCFPS)	:	3.22	(2.17)
		As at September 30, 2026	**As at June 30, 2026**
iv) Net Asset Value (NAV)	:	2,54,40,40,176.85	2,53,15,32,029.48
v) Net Asset Value Per Share (NAVPS)	:	84.64	84.23

Significant Deviation:

EPS:	In the current period, profit after tax and EPS increased compared to the previous period due to increased product sales and reduced production and operating costs.
NOCFPS:	Operating cash flow increased significantly due to higher collections from receivables and reduced expenses.

The details of the First Quarter (Q1) Un-Audited Financial Statements for the period ended September 30, 2026 are available in the website of the Company at **www.jmisyringe.com**

By the order of the Board

Dated: November 12, 2026, Dhaka

Muhammad Tarek Hossain Khan
Company Secretary